Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | STAT6 | P42226 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | GMNN | O75496 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | KCNA4 | P22459 | 1/20 | 0.30 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.30 |
| ▸ | KCNAB1 | Q14722 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1829037 | 1.00 | FFAR3 (0.35) | FFAR3MAPK1TP53NFKB1CYP2C19 | |
| SCHEMBL877771 | 1.00 | FFAR3 (0.35) | FFAR3MAPK1TP53NFKB1CYP2C19 | |
| SCHEMBL2035911 | 0.98 | FFAR3 (0.33) | FFAR3MAPK1TP53NFKB1CYP2C19 | |
| SCHEMBL2657443 | 0.83 | KCNA4 (0.31) | KCNA4KCNA1KCNAB1 | |
| SCHEMBL335112 | 0.82 | — | — | |
| SCHEMBL948961 | 0.82 | — | — | |
| SCHEMBL9981013 | 0.79 | FFAR3 (0.41) | FFAR3MAPK1TP53NFKB1CYP2C19 | |
| SCHEMBL7567329 | 0.79 | FFAR3 (0.33) | FFAR3MAPK1TP53NFKB1CYP2C19 | |
| SCHEMBL5363480 | 0.77 | CA1 (0.33) | KCNA4KCNA1KCNAB1 | |
| Lithium Ion SCHEMBL2035907 | 0.77 | KCNA4 (0.32) | KCNA4KCNA1KCNAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557847-B2 | Synergistic modulation of FLT3 kinase using a FLT3 inhibitor and a farnesyl transferase inhibitor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-10-15 | — | — | US | disclosed |
| US-8227627-B2 | Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same | ALLTRANZ INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20110243884-A1 | BIODEGRADABLE POLYMER - BIOACTIVE MOIETY CONJUGATES | THE BIONICS INSTITUTE OF AUSTRALIA (AU) | 2011-10-06 | — | — | US | disclosed |
| EP-2355853-A1 | BIODEGRADABLE POLYMER - BIOACTIVE MOIETY CONJUGATES | The Bionic Ear Institute (AU) | 2011-08-17 | — | — | EP | disclosed |
| EP-2340271-A1 | POLYMER-BIOACTIVE AGENT CONJUGATES | The Bionic Ear Institute (AU) | 2011-07-06 | — | — | EP | disclosed |
| EP-2315754-A1 | PYRIMIDYL SULFONAMINDE DERIVATIVE AND ITS USE FOR THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | AstraZeneca AB (SE) | 2011-05-04 | — | — | EP | disclosed |
| WO-2010007427-A1 | PYRIMIDYL SULFONAMINDE DERIVATIVE AND ITS USE FOR THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016275-A1 | NOVEL COMPOUND 395 | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| US-20090197913-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | BAUMANN CHRISTIAN ANDREW | 2009-08-06 | — | — | US | disclosed |
| US-20090143462-A1 | Products of Tetrahydrocannabinol, Compositions Comprising Prodrugs of Tetrahydrocannabinol and Methods of Using the Same | ALLTRANZ (US) | 2009-06-04 | — | — | US | disclosed |
| WO-2005082892-A2 | TRIAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-09-09 | — | — | WO | disclosed |
| US-4234490-A | Intermediates in the synthesis of vitamin E | HOFFMANN-LA ROCHE INC. (US) | 1980-11-18 | — | — | US | disclosed |
| US-4201879-A | Hydroquinones | HOFFMANN-LA ROCHE INC. (US) | 1980-05-06 | — | — | US | disclosed |
| US-4153614-A | Synthesis of (S)-(+)-6-hydroxy-2,5,7,8-tetramethylchroman-2-methanol and intermediates therein | HOFFMANN-LA ROCHE INC. (US) | 1979-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | VIP, EIF2AK2, PREP | FFAR3 4112/4885MAPK1 2575/4885TP53 561/4885 |
| US-20110243884-A1 | BIODEGRADABLE POLYMER - BIOACTIVE MOIETY CONJUGATES | BMP2, MKI67, FGF2 | FFAR3 2070/4885MAPK1 2688/4885TP53 1011/4885 |
| US-20090143462-A1 | Products of Tetrahydrocannabinol, Compositions Comprising Prodrugs of Tetrahydrocannabinol and Methods of Using the Same | CNR2, CNR1, FAAH | FFAR3 360/4885MAPK1 3921/4885TP53 3790/4885 |
| US-20100016275-A1 | NOVEL COMPOUND 395 | CCL5, CCL2, CCL11 | FFAR3 1268/4885MAPK1 355/4885TP53 3096/4885 |
| US-20090197913-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | FLT3, MCL1, CSF1R | FFAR3 3767/4885MAPK1 766/4885TP53 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.